These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 21173125)

  • 41. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
    Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
    Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features.
    Andersen MT; Andersen MK; Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2008 May; 22(5):951-5. PubMed ID: 18273044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
    Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
    Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
    Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
    Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low frequency of FLT3 gene internal tandem duplication and activating loop mutation in therapy-related acute myelocyticleukemia and myelodysplastic syndrome.
    Au WY; Fung AT; Ma ES; Liang RH; Kwong YL
    Cancer Genet Cytogenet; 2004 Mar; 149(2):169-72. PubMed ID: 15036894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia.
    Radojkovic M; Tosic N; Colovic N; Ristic S; Pavlovic S; Colovic M
    Ann Clin Lab Sci; 2012; 42(2):186-90. PubMed ID: 22585616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.
    Huang Q; Chen W; Gaal KK; Slovak ML; Stein A; Weiss LM
    Br J Haematol; 2008 Jul; 142(3):489-92. PubMed ID: 18477048
    [No Abstract]   [Full Text] [Related]  

  • 54. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
    Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
    Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
    Choschzick M; Bacher U; Ayuk F; Lebeau A
    J Clin Pathol; 2010 Jun; 63(6):558-61. PubMed ID: 20360144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
    Schnittger S; Bacher U; Kern W; Alpermann T; Haferlach C; Haferlach T
    Leukemia; 2011 Aug; 25(8):1297-304. PubMed ID: 21537333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.